Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.62 |
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096075 | 0.88 | RAB9A (0.64) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL21962990 | 0.83 | RAB9A (0.57) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL2606735 | 0.83 | RAB9A (0.57) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL13144514 | 0.81 | MAPT (0.70) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL14820139 | 0.81 | MAOA (0.48) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL914552 | 0.81 | RAB9A (0.68) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL2452993 | 0.80 | RAB9A (0.58) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL2445404 | 0.80 | RAB9A (0.55) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL18971791 | 0.80 | RAB9A (0.57) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL163667 | 0.79 | RAB9A (0.66) | RAB9ANPC1MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996924-B | Substituted pyrazolyl compounds and methods of use thereof | 诺华医药股份公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| CN-115996924-A | Substituted pyrazolyl compounds and methods of use thereof | 奇努克医疗加拿大公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4153585-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Chinook Therapeutics Canada, Inc. (CA) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021234547-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | CHINOOK THERAPEUTICS CANADA, INC. (CA) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021234547-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | CHINOOK THERAPEUTICS CANADA, INC. (CA) | 2021-11-25 | — | — | WO | disclosed |
| EP-1853586-B1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130150366-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA, INTELLECTUAL PROPERTY (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8399489-B2 | Antibacterial piperdine derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| EP-1853586-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087543-A1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150366-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, CFTR | RAB9A 965/4885NPC1 266/4885MAPT 2041/4885 |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | LDHA, LDHB, XDH | RAB9A 3319/4885NPC1 1875/4885MAPT 2497/4885 |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | PIR, HAMP, AMPD2 | RAB9A 119/4885NPC1 966/4885MAPT 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.